Prior studies have demonstrated that spironolactone is an effective second-line treatment option for postadolescent acne, but has notable side effects. Data are, however, limited. We therefore present a 4-year retrospective study evaluating 291.5 patient-years of spironolactone for the treatment of acne. Our results showed that 86% of patients improved on spironolactone therapy. Further, patients who improved showed minimal side effects, supporting recent evidence that spironolactone is a safe option for acne treatment with a low risk of short-term adverse effects such as hyperkalemia. It is suggested that our study encourages consideration of spironolactone for postadolescent acne.

Keywords:
Female, Acne, Postadolescent acne
1.
Bhate K, Williams HC: Epidemiology of acne vulgaris. Br J Dermatol 2013;168:474-485.
2.
Kim GK, Del-Rosso JQ: Oral spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinical based on current data and clinical experience. J Clin Aesthet Dermatol 2012;5:37-50.
3.
Plovanich M, Weng QY, Mostaghimi A: Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol 2015;151:941-944.
4.
Shaw JC: Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000;43:498-502.
5.
Katsambas AD, Dessinioti C: Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol 2010;28:17-23.
6.
Yin NC, McMichael AJ: Acne in patients with skin of color: practical management. Am J Clin Dermatol 2014;15:7-16.
7.
Turoskwi CB, James WD: The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatment-resistant acne vulgaris. Adv Dermatol 2007;23:155-163.
8.
Dreno B, Thiboutot D, Gollnick H, Bettoli V, Kang S, et al: Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol 2014;24:330-334.
9.
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, et al: Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:1-62.
10.
Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M: Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol 2013;37:870-875.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.